The first patient with advanced non–small cell lung (NSCLC) in the phase 1/2 Acclaim-1 clinical trial had been dosed with quaratusugene ozeplasmid (Reqorsa) in combination with osimertinib (Tagrisso) after disease progression on osimertinib alone, according to a press release issued by Genprex, Inc.1
Quaratusugene ozeplasmid is an immunogene therapy, designed to be injected directly into tumor cells to interrupt cell signaling pathways and recreate pathways for apoptosis in cancer cells. Quaratusugene ozeplasmid also modulates the immune response against cancer cells and blocks the development of drug resistance.
“This is an exciting milestone for Genprex that we believe brings us one step closer to achieving our goal to validate the potential benefits of Reqorsa in NSCLC patients who have life-limiting disease and few treatment options,” stated Mark S. Berger, MD, chief medical officer of Genprex, in a press release. “Based on both the preclinical data and previous clinical data, Reqorsa has the potential to improve the response to current targeted therapies, such as Tagrisso, for this study patient population. We look forward to continuing to advance this important trial.” Read more.